Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Georgetown University · Georgetown University Medical Center · +21 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
883
total citations
- FWCI
- 42.43
- Percentile
- 100%
- References
- 31
Citations per year
Authors
222- SMSandra M. SwainCorresponding
Georgetown University, Georgetown University Medical Center, Vince Lombardi Cancer Clinic, MedStar Health
- DMDavid Miles
Mount Vernon Cancer Centre
- SKSung‐Bae Kim
Ulsan College, Asan Medical Center, University of Ulsan
- YIYoung‐Hyuck Im
Samsung Medical Center, Sungkyunkwan University
- SISeock‐Ah Im
Seoul National University Hospital
Topics & keywords
Topics
Keywords
- Pertuzumab
- Docetaxel
- Trastuzumab
- Medicine
- Metastatic breast cancer
- Cleopatra
- Placebo
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.